Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

Completed · Phase 3 · Has a placebo group

Conditions studied: Hepatocellular Carcinoma

In brief

The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with standardized radiofrequency ablation (sRFA).

Key facts

Study ID

NCT02112656

Run by

Imunon

People needed

554

Starts

2014-06-01

Expected to finish

2020-04-27

Last updated by the study team

2024-08-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥ 18 years of age.
• Diagnosed with a single HCC lesion ≥ 3.0 cm but ≤ 7.0 cm in maximum diameter based on diagnosis at screening.
• Subjects meeting the American Association for the Study of Liver Disease (AASLD) criteria may be randomized without a biopsy, but will undergo a biopsy during the RFA procedure unless contraindicated or unattainable.
• Subjects not meeting the AASLD criteria for HCC will need a biopsy to confirm HCC prior to randomization.
• Be an appropriate candidate for receiving RFA as a medically indicated treatment as evaluated by the following factors:
• The position and accessibility of the target lesion allows for the safe administration of multiple ablation cycles or deployments to achieve a probe dwell time of ≥ 45 minutes.
• Not a candidate for surgical resection according to the local guidelines for resection and in the Investigator's judgment.
• Child-Pugh Class A without either current encephalopathy or ascites.
• Left Ventricular Ejection Fraction (LVEF) ≥ 50%.
• Eastern Cooperative Oncology Group (ECOG) performance status 0.
• Willing to sign an informed consent form, indicating awareness of the investigational nature of this study that is in keeping with the policies of the institution.

You may not qualify if…

• Is scheduled for liver transplantation
• Expected ablation volume > 30% of total liver volume or removal of 3 hepatic segments
• More than 1 lesion identified during baseline.
• Have previously received therapeutic treatment for HCC outside the study protocol or is expected to receive concomitant HCC treatment prior to PFS event.
• Have serious medical illnesses including, but not limited to, congestive heart failure, myocardial infarction or cerebral vascular accident within the last six months, or life threatening cardiac arrhythmias.
• Have previously received any anthracycline outside the protocol
• Have extrahepatic metastasis.
• Have portal or hepatic vein tumor invasion/thrombosis.
• Have body temperature >101ºF (38.3ºC) immediately prior to study treatment.
• Baseline laboratories (repeat lab tests are permitted to evaluate eligibility during the Screening Period. Lab results must be within protocol range prior to study treatment.)
• Absolute neutrophil count < 1500/mm3
• Platelet count < 75,000/mm3
• Hgb < 10.0 g/dL (unless the hemoglobin value has been stable, the subject is cardiovascularly stable, asymptomatic and judged able to withstand the RFA procedure) Note: If clinically indicated, subjects may receive platelets or packed red blood cell (RBC) transfusions and be re-evaluated after condition is treated.
• Baseline Chemistry
• Serum creatinine ≥ 2.5 mg/dL or calculated creatinine clearance (CrCl) ≤25.0 mL/min.
• Serum bilirubin > 3.0 mg/dL.
• Serum albumin < 2.8 g/dL.
• Have any known allergic reactions to any of the drugs or liposomal components or intravenous imaging agents that prohibit the ability to complete the imaging requirements.
• Are pregnant or breast-feeding. In women of childbearing potential, a negative serum pregnancy test is required prior to study treatment.
• Women of childbearing potential and men who are not practicing an acceptable form of birth control (i.e. diaphragm, cervical cap, condom, surgical sterility or birth control pills. Women whose partner has or men who have undergone a vasectomy must use a second form of birth control).
• Have INR > 1.5 times the institution's upper normal limit (UNL), except in subjects who are therapeutically anticoagulated for medical conditions unrelated to HCC such as atrial fibrillation. Subjects may be re-screened after condition is treated or anticoagulant is withheld.
• Have contraindications to receiving doxorubicin hydrochloride (HCl).
• Are being treated with other investigational agents.
• Use of an investigational drug outside this study within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
• Have other concurrent malignancy (subjects with treated squamous cell carcinoma of the skin or basal cell carcinoma of the skin may be included), evidence of extrahepatic cancer from their primary malignancy, or ongoing, medically significant active infection.

Where it is running

• Toronto General Hospital — Toronto, Ontario, Canada
• Mengchao Hepatobiliary Hospital of Fujian Medicatl University — Fuzhou, Fujian, China
• Xijing Hospital — Xi'an, Shaanxi, China
• Peking University First Hospital — Beijing, China
• Beijing Cancer Hospital, School of Oncology, Peking — Beijing, China
• 302 Military Hospital of China — Beijing, China
• Beijing Hospital of the Ministry of Health — Beijing, China
• Chinese PLA General Hospital — Beijing, China
• West China Hospital of Sichuan University — Chengdu, China
• The Second Hospital of Dalian Medical University — Dalian, China
• Guangdong General Hospital — Guangdong, China
• Hunan Cancer Hospital — Hunan, China
• The First Hospital of Jilin University — Jilin City, China
• Zhongshan Hospital, Fudan University — Shanghai, China
• The Sixth People's Hospital of Shenyang — Shenyang, China
• The 3rd Hospital of Tianjing — Tianjin, China
• The First Hospital of Zhejiang — Zhejiang, China
• Zhejiang Cancer Hospital — Zhejiang, China
• Institut für Diagnostische und Radiologische Therapie del Uniklinik Frankfurt — Frankfurt, Germany
• Universitaetsklinikum des Saarlandes, Klik fuer Allgemeine Chirurgie, Viszeral-, Gefaess und Kinderchirurgie — Homburg, Germany
• Klinikum rechts der Isar, II. Medizinische Klinik und Poliklinik (Gastroenterologie) — München, Germany
• Universitätsklinikum Regensburg, Institut für Röntgendiagnostik — Regensburg, Germany
• Queen Mary Hospital — Hong Kong, Hong Kong
• Cisanello Hospital, Division of Diagnostic Imaging and Intervention — Pisa, Italy
• UCLA Department of Medicine — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.